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Meta-analysisAbstract The objective of this studywas to develop quantitativemodels to delineate the net efﬁcacy of
taspoglutideon fastingplasmaglucose (FPG)and glycosylated hemoglobin (HbA1c) from the response
of placebo in type 2 diabetes patients, and further ﬁnd pharmacodynamic potency of taspoglutide and
FPGfor half ofmaximumreduction responses ofFPGandHbA1c, respectively. Several PDdata about
taspoglutide treatments for type 2 diabetes patients were digitalized from the published papers related
with the clinical development of taspoglutide. The model based meta-analysis (MBMA) studies for
FPG and HbA1c were performed with Monolix 4.2 software. The MBMA successfully described the
effects of placebo and taspoglutide on pharmacological indexes of FPG and HbA1c through mono
andmultiple combination therapies in clinical trials. The pharmacodynamic potency (25.3 pmol/l) pro-
duced 50% of maximum responses of FPG (2.39 mmol/l) from the responses of placebo for FPG
(0.371 mmol/l); the response change of FPG (1.81 mmol/l) affected 50% of maximum response
change (1.74%) forHbA1c from the response of placebo (0.253%). The leveraging prior knowledge
from the longitudinalMBMAwill be utilized to guide clinical development of taspoglutide and further
support study designs including optimization of dose and duration of therapy.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
With a steady increase in the prevalence of diabetes from 1980
to 2011, it is estimated that by the year 2030, 552 million peo-
ple will have diabetes (Whiting et al., 2011), thus the great bur-
den will be brought worldwide by the huge increase in type 1
and 2 diabetes population, of which type 2 diabetes people
account for about 90–95% of all diagnosed cases of diabetes
242 H.Q. Li et al.(Gavin et al., 2010; Nyenwe et al., 2011). Although current
therapies for type 2 diabetes include lifestyle modiﬁcation of
diet and exercise as ﬁrst-line therapy, pharmacotherapy is con-
sidered an essential component for effective glycemic control
(Nathan, 2009). Glucagon-like peptide-1 (GLP-1) receptor
agonists are a novel class of pharmacotherapies that provide
effective glycemic control with low risk of hypoglycemia and
weight loss (Drucker, 2007; Sebokova et al., 2010a). Taspoglu-
tide is a long-acting human GLP-1 analogue and considered to
have equivalent potency to natural GLP-1 (Nauck et al., 2009).
This GLP-1 analogue has been shown to elicit a long-lasting
incretin effect, and sustained glycemic control (Raz et al.,
2012).
Taspoglutide contains aminoisobutyric acid which is cova-
lently attached to the GLP-1 sequence at positions 8 and 35 of
the native GLP-1 peptide (Dong et al., 2011). These structure
modiﬁcations prolong the half-life of the circulating complex
without otherwise changing its biological activity. Also, appar-
ently, the aminoisobutyric acid molecule sterically inhibits
DPP-4 enzyme from degrading taspoglutide (Sebokova et al.,
2010b). Taspoglutide shows high binding afﬁnity to the human
GLP-1 receptor (Pratley et al., 2013) and its biological activity
is not affected through assessment of its relative activity on
cyclic adenosine monophosphate stimulation (Sebokova
et al., 2010b). Its resistance to DPP-4 enzyme degradation
and a zinc-based sustained release formulation confer an
extended half-life and allow for QW subcutaneous administra-
tion (Ratner et al., 2010). Several multiple dosing regimens in
clinical trials have showed that taspoglutide 10 or 20 mg com-
pared with placebo to patients with type 2 diabetes reduced
FPG levels, stimulated insulin secretion and reduced glucagon
levels with weight loss (Nauck et al., 2009; Bergenstal et al.,
2012; Henry et al., 2012; Raz et al., 2012).
We present here quantitative models to describe time
courses of FPG and HbA1c, and these models provide linkage
between drug and responses. Such models can leverage prior
knowledge from clinical studies, and conduct comparison of
competing drugs (Gross et al., 2013), and make prediction of
unobserved clinical outcomes (Gibbs et al., 2012).
The present study was performed to delineate the net effects
of taspoglutide on FPG and HbA1c from the responses of pla-
cebo in type 2 diabetes patients, and further ﬁnd pharmacody-
namic potency (IC50_F and IC50_H) for half of maximum
reduction responses of FPG and HbA1c, respectively. The ret-
rospectively integrated prior knowledge from clinical studies
will be utilized to guide clinical development and application
of taspoglutide in future.2. Methods
2.1. Selection of studies
All studies that investigated the efﬁcacy of taspoglutide in clin-
ical trials about pharmacological indexes of FPG and HbA1c
were considered in these quantitative models. Data were
searched in PubMed/MEDLINE, Google scholar search and
clinical trial registries lasting between inception and February
2014, and the medical subject heading terms and text words
from electric databases included efﬁcacy, pharmacokinetics,
pharmacodynamics, type 2 diabetes, clinical trial, FPG and
HbA1c for taspoglutide. Data in each article must becomposed of FPG and HbA1c, and the multiple dosing
regimens should include placebo, 10 and 20 mg doses and
the PD data were only from efﬁcacy of placebo, 10 and
20 mg doses on patients through chronic treatments.
Mean FPG and HbA1c results were collected from the ﬁg-
ures, tables and values reported in article content. Data from
the articles were transformed to change values from baselines
if the actual measurements were used to depict the efﬁcacy in
clinical studies, and the each PD group data must have the
same units and homogeneous properties. All references cited
in this study were carefully reviewed to identify the PD data
for ﬁnal model development. Two investigators independently
extracted data from eligible studies, and ﬁnally reached an
agreement on inclusion criteria for ﬁnal data entry.
Two PD endpoints were used to summarize the mean efﬁ-
cacy results of taspoglutide after multiple dosing regimens in
clinical trials. For all studies, the study protocols were
approved by the local ethics and research committees, and
written informed consents were obtained from all subjects
enrolled in clinical studies.
2.2. Metrics for PD modeling
The average plasma concentration between 2nd and 4th week
(Cavg.(2 w–4 w) value) of taspoglutide (20 mg dose per dosing
regimen group), which was obtained from the published paper
(Ratner et al., 2010), was directly used as metric to characterize
the efﬁcacy results (FPG) when taspoglutide 20 mg was subcu-
taneously administrated to patients with type 2 diabetes. The
maximum reduction responses (Dmax_F) in FPG for taspo-
glutide 10 and 20 mg doses were used as metrics for HbA1c
data model development in the taspoglutide group. The met-
rics (placebo, 10 and 20 mg doses) ﬁnally used for FPG and
HbA1c data model development are shown in Supplementary
Table 1.
2.3. Software
Two quantitative models for taspoglutide PD indexes were
developed and estimated on the available digitalized measures,
using Monolix 4.3 software (http://software.monolix.org)
(Bouazza et al., 2012; Laouenan et al., 2013). Parameters of
PD models were estimated by computing the maximum likeli-
hood estimator using the stochastic approximation expectation
maximization (SAME) algorithm method. The model building
processes were guided by visual inspection of goodness-of-ﬁt
(GOF) and change of 2 times the log likelihood (OFV),
Akaike Information Criteria (AIC) and Bayesian Information
Criteria (BIC) obtained from Monolix. Prediction distribution
graphics were obtained using the Monolix 4.3 software, and
other graphics were obtained from R 2.15 (http://www.R-pro-
ject.org) and RStudio 0.97 (http://www.rstudio.com) program.
2.4. Modeling strategy
The utilization of quantitative model (Gibbs et al., 2012) was
extended to delineate the net efﬁcacy of placebo-adjusted
taspoglutide in clinical trials. The placebo and taspoglutide
responses over time were estimated and processed in 3 general
steps. Firstly, the placebo responses over time for FPG and
HbA1c were independently estimated and the parameter
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drug responses simultaneously. Secondly, the Emax equations
and metrics were used to develop ﬁnally combined response
models including changes of FPG and HbA1c for placebo
and taspoglutide. Finally various statistical models were inves-
tigated, and the most appropriate was selected for use in ﬁnally
combined model development.
2.5. PD modeling
The drug and placebo directly acted on FPG and indirectly
regulated HbA1c changes from the baselines.
The time courses of placebo response were predicted
according to Eq. (1):
Placebo responses;iðtÞ ¼ Pmax s;i  ð1 eKp s;itÞ ð1Þ
The time courses of drug response were predicted according to
Eq. (2):
Drug responses;iðtÞ ¼ placebo responses;iðtÞ
þ Dmax s;imetric s;i
DI50 s;iþmetric s;i  ð1 ekdrug s;itÞ þ es;i
ð2Þ
where s is the identiﬁcation for PD: 1 and 2 for FPG and
HbA1c, respectively, and i represents individual PD index. Pla-
cebo_response (t) and drug_response (t) represent the placebo
and drug responses over time, respectively; Pmax and Dmax
are the maximum effects of placebo and drug, respectively;
Kp and Kdrug represent the ﬁrst order rate constants in the
reduction of FPG and HbA1c for placebo and taspoglutide;
The metric variables in Eq. (2) are the metrics associated with
half-maximal responses of FPG and HbA1c, e is the random
residual error. Two DI50 estimates represent pharmacody-
namic potency of drug and FPG on the responses of FPG
and HbA1c, respectively, when the drug was administrated
to patients.
2.6. Statistical model
The between variability of selected PD parameters was
described by the exponential and addictive models. The below
exponential and addictive models are used to describe the
between variability of selected PD parameters:
Pi ¼ Ppop  expðgpiÞ ð3Þ
Pi ¼ Ppop þ gpi ð4Þ
where individual parameters for exponential model mainly
include Kp and Kdrug, while individual parameters for addic-
tive model mainly include Pmax, Dmax and IC50; Pi is the indi-
vidual parameter value, Ppop is its typical population value,
and gPi is an independent random variable normally distrib-
uted with the mean of zero and standard deviation xpi.
The combined error models of the residual error were
applied to FPG (Eq. (5)) and HbA1c (Eq. (6)) data:
Y ¼ Fþ b  Fc  e ð5Þ
Y ¼ Fþ ðaþ b  FcÞ  e ð6Þ
where Y is the observation; F is the corresponding model pre-
diction; a, b and c represent residual error parameters; e isassumed to be an independent and normally distributed ran-
dom variable with the mean of zero and standard deviation r.
The assessments of model adequacy and decision about
increasing model complexity were driven by the data and
guided by GOF. All parameter estimates were reported with
the relative standard error of estimates (R.S.E %).
2.7. Model validation
The ﬁnal models were internally examined by GOF, which
included plots of normalized prediction distribution error
(NPDE) (Brendel et al., 2006) vs. time and IPRED, and plots
of population prediction (PRED) and IPRED vs. observation
(DV). Other diagnostics included the OFV and the precision of
the parameter estimates.
The ﬁnally established models were also externally vali-
dated. Additional PD data (Rosenstock et al., 2013) were ret-
rospectively collected from a group of 797 patients with type 2
diabetes who met the same inclusion criteria as the ﬁnal model
building group. FPG and HbA1c data were predicted by ﬁxing
the parameters in the structural and statistical model to the
parameter estimates in the ﬁnal model using post hoc Bayesian
forecasting with Monolix software. The predictive power was
determined by comparing the predicted values with the corre-
sponding observed values. Bias (mean prediction error [MPE])
and precision (mean absolute prediction error [MAPE]) were
calculated (Han et al., 2011), using Eqs. (7) and (8):
MPE ¼
PðPDipred  PDobsÞ
N
 100% ð7Þ
MAPE ¼
P
PDipred  PDobs




N
 100% ð8Þ
where N denotes the number of observations, PDipred and
PDobs are individual prediction and observation values of
PD data, respectively.3. Results
3.1. PD Data
The computer searches yielded 9 publications (Nauck et al.,
2009, 2013; Ratner et al., 2010; Bergenstal et al., 2012;
Henry et al., 2012; Raz et al., 2012; Hollander et al.,
2013; Pratley et al., 2013; Rosenstock et al., 2013) which
were deemed appropriate for inclusion and used to process
pharmacometric assessments based multiple PD indexes. In
this literature search study, 8 clinical trial data were chosen
to include for model development and 1 clinical trial data
(Rosenstock et al., 2013) were used for external model val-
idation, and a total of 3702 patients participated in clinical
trials of placebo, 10 and 20 mg doses of taspoglutide over
weeks 8–52. The therapeutic regimens mainly included
taspoglutide monotherapy with diet control and exercise,
or taspoglutide in combination with metformin, metformin
or/and sulphonylurea, metformin or/and TZD, and metfor-
min plus TZD in clinical trials. Table 1 provides a sum-
mary of available clinical data involving the effects of
taspoglutide on the FPG and HbA1c in randomized clini-
cal trials.
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244 H.Q. Li et al.3.2. Metrics for PD modeling
The metrics available to use for FPG and HbA1c data model-
ing are summarized in Supplementary Table 1. The metrics for
FPG data were directly derived from the digitalized taspoglu-
tide concentrations between 2nd and 4th week (Ratner et al.,
2010). The three individual concentrations for 20 mg doses
were averaged and the average value was directly used as met-
ric for PD modeling of subsequent taspoglutide 20 mg dose.
The metric for 10 mg dose of taspoglutide was directly calcu-
lated from simple arithmetic of the average concentration
value of 20 mg dose, as the exposure of taspoglutide appeared
dose proportional once weekly (Ratner et al., 2010). The met-
ric for placebo was set to zero, as no drug concentrations were
involved in the pharmacokinetics in clinical trials. An explor-
atory analysis of the relationship between the metric and
FPG was conducted lasting from 8 to 52 weeks of placebo,
taspoglutide 10 and 20 mg. Overall, FPG over time was ﬁtted
well by quantitative models, as seen in Figs. 1 and 2.
The metrics for HbA1c modeling were derived from the
population prediction values for taspoglutide 10 and 20 mg
in FPG modeling. However, the metric for placebo HbA1c
data modeling were set to zero, as the drug concentration
was not involved in treatment response. The exploratory anal-
ysis approach for taspoglutide concentration-FPG was also
used to characterize relationship between FPG and HbA1c,
which was also adequately described by quantitative model,
as seen in Fig. 2.
3.3. FPG
The time courses of placebo and drug responses for FPG are
shown in Fig. 1 and structure parameter estimates and individ-
ual trial variability are presented in Table 2. In the placebo
group, the population prediction (Pmax_F) of FPG change
from baseline was 0.371 mmol/l (Fig. 1A), which reﬂected
the overall trend of FPG when the placebo was given to the
patients. While in the drug group, the population prediction
(Dmax_F) of FPG change from baseline was 2.39 mmol/l
(Fig. 1B), which reﬂected the trends of FPG reduction when
the doses (10 and 20 mg) were given to the patients. Compared
with placebo responses, the drug responses of two doses were
much more signiﬁcant in FPG reduction (Fig. 1A vs. Fig. 1B).
Overall, prediction distribution of FPG reductions for the drug
group demonstrated that quantitative model could adequately
ﬁt the observed mean values from published papers.
An exponential function for combined placebo and drug
responses adequately described the changes of placebo and drug
responses over time with a Kp_F of 0.781 weeks1 and a
Kdrug_F of 2.0 weeks1, and the drug concentration of taspo-
glutide (IC50_F) was about 25.3 pmol/l which could produce
50% of maximum efﬁcacy (Dmax_F = 2.39 mmol/l) in clini-
cal trials. The estimated kdrug_F was 2.0 weeks1, which corre-
sponds to a half-life of 2.4 days. Using the estimated kdrug_F
value, the steady-state reduction in FPG was predicted to be
achieved after approximately 12 days or 1.7 weeks (Fig. 1B).
3.4. HbA1c
The time courses of placebo and drug responses for HbA1c are
shown inFig. 2 and structure parameter estimates and individual
Figure 1 Observed and prediction distribution of FPG response over time in A (placebo response, change from baseline) and B (drug
response, change from baseline). The color areas represented the 95% conﬁdence interval of the prediction around the simulated
percentiles, the solid dots were mean FPG values from the literatures and the solid line represented the median prediction.
Figure 2 Observed and prediction distribution of HbA1c response over time in A (placebo response, change from baseline) and B (drug
response, change from baseline). The color areas represented the 95% conﬁdence interval of the prediction around the simulated
percentiles, the solid dots were mean FPG values from the literatures and the solid line represented the median prediction.
Table 2 Parameter estimates from quantitative model for FPG.
Parameter Estimate R.S.E (%) ITVd (%)
Pmax_F(mmol/l)e 0.371 35 29.8
Kp_F (1/week)e 0.781 43 37.8
Dmax_F (mmol/l) 2.39 6 24.8
IC50_F (pmol/l) 25.3 0 5.43
Kdrug_F (1/week) 2.0 2 12.5
b 0.194 8
c 0.182 37
R.S.E represented relative standard error; F represents FPG; IC50_F represents pharmacodynamic potency of drug on the response of FPG when
the drug was administrated to patients.
d ITV represents inter trial viability.
e Parameter estimates for FPG in placebo were ﬁxed in ﬁnally combined PD model.
Model-based meta-analysis to delineate the net efﬁcacy of taspoglutide 245trial variability are presented in Table 3. In the placebo group,
the population prediction (Pmax_Hb) of HbA1c change from
baseline was 0.253% (Fig. 2A), which reﬂected the overall
trend of HbA1c when the placebo was given to the patients.While in the drug group, the population prediction (Dmax_Hb)
of HbA1c change from placebo response was1.74% (Fig. 2B).
Comparedwith placebo responses, the drug reduction responses
of two doses were much more signiﬁcant (Fig. 2A vs. Fig. 2B),
Table 3 Parameter estimates from quantitative model for
HbA1c.
Parameter Estimate R.S.E (%) ITVd (%)
Pmax_Hb (%)e 0.253 26 15.2
Kp_Hb (1/week) e 0.382 23 14.7
Dmax_Hb (%) 1.74 8 8.65
IC50_H (mmol/l) 1.81 15 26.8
Kdrug_Hb (1/week) 0.249 13 19.9
a 0.00532 16
b 0.0717 13
c 0.239 66
R.S.E represented relative standard error; Hb represents HbA1c;
IC50_H represents pharmacodynamic potency of FPG on the
response of HbA1c when the drug was administrated to patients.
d ITV represents inter trial viability.
e Parameter estimates for HbA1c in placebo were ﬁxed in ﬁnally
combined PD model.
246 H.Q. Li et al.but the responses between dose 10 and 20 mg did not show sig-
niﬁcant differences in the reduction of HbA1c. Overall, predic-
tion distribution of HbA1c changes for the drug group
demonstrated that quantitative model could adequately ﬁt the
observed mean values from published papers.
An exponential function for combined placebo and drug
responses adequately described the changes of placebo and
drug response over time with an Kp_Hb of 0.382 weeks1Time(weeks)
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Figure 3 Diagnostic plots: normalized prediction distribution error
population prediction and individual prediction (PRED) vs. observatiand an Kd_Hb of 0.249 weeks1, and the reduction of FPG
(IC50_H) in plasma concentration was about 1.81 mmol/l
which could produce 50% of maximum efﬁcacy
(Dmax_Hb = 1.74%) in clinical trials. The estimated
kdrug_Hb was 0.249 weeks1, which corresponds to a half-life
of 2.8 weeks. Using the estimated kdrug_Hb value, the steady-
state reduction in HbA1c was predicted to be achieved after
approximately 14 weeks or 3.5 months (Fig. 2B).
3.5. Model validation
For internal evaluation, the combined diagnostic plots for
quantitative models of FPG and HbA1c are shown in Fig. 3.
GOF plots suggested that the models adequately ﬁtted FPG
and HbA1c data. The plots of NPDE vs. TIME and NPDE
vs. IPRED, showed a symmetric distribution around zero
(Fig. 3A and B). The plots of DV vs. PRED and DV vs.
IPRED indicated that the model adequately described the
observations (Fig. 3C and D).
In the external validation as shown in Fig. 4, the individual
predictions of FPG for 10 and 20 mg doses were in agreement
with observed values with slight bias, with an MPE of 40.5%
and 36.1%, respectively, and a precision of 40.5% and
38.1%, respectively. The individual predictions of HbA1c for
dose 10 and 20 mg were not biased, with an MPE of 16.6%
and 0.81%, respectively, and a precision of 16.6% and
11.1%, respectively. Overall, the individual predictions of
HbA1c for 10 and 20 mg doses were much more consistentIPRED(PD)
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Figure 4 One clinical PD data were used to validate the ﬁnal model. Observed and predicted PD response (change from baseline) over
time in A and B (taspoglutide 10 and 20 mg for FPG and HbA1c), respectively. The open cycle and solid line symbols represented the
mean observed and simulated PD changes, respectively. The mean PD data were digitalized from the paper published by Rosenstock et al.
(2013).
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erable precisions, compared with predictions of FPG for 10
and 20 mg doses.
4. Discussion
The MBMA approach has been developed and used to assess
the comparative efﬁcacy of different medications (Gross et al.,
2013). This approach can more efﬁciently incorporate longitu-
dinal and/or dose–response data from trials of different dura-
tions and with different sampling time-points, which is
distinguished with the methodology of conventional meta-
analysis by manner (Ahn and French, 2010; Gross et al.,
2013). This analysis method has shown its beneﬁt in summariz-
ing the clinical results from a large number of trials to develop
a PK/PD model (Kimko et al., 2012). Developed model can be
utilized to predict the clinical outcomes following administra-
tion of a drug with different dosing regimens (Gibbs et al.,
2012).
In this study, we had access to the intensely sampled longi-
tudinal PD data from patients in clinical trials that substan-
tially evaluated the efﬁcacy with FPG and HbA1c of
taspoglutide; these data were utilized to develop quantitativemodels with speciﬁc focus on leveraging information of taspo-
glutide in clinical drug development. Large samples and clini-
cal trials of taspoglutide for FPG and HbA1c can further
provide insight into the relationship between efﬁcacy and drug,
and will give clinical guideline for treatment of type 2 diabetes
patients in the future.
The MBMA has provided novel information on the quan-
titative characterization of taspoglutide efﬁcacy in clinical tri-
als. In PD data modeling, two different kinds of metrics were
used for model-based analysis including average drug concen-
tration for FPG data and model population prediction value
for HbA1c data. Emax model was commonly used to link
PK with PD in which the drug concentrations acted as linkage
to efﬁcacy results (Gao and Jusko, 2011). The 8- to 52-week
taspoglutide concentrations for different dosing regimens were
not directly obtained in publications, so the average concentra-
tions (0, 59.85 and 119.7 pmol/l for placebo, taspoglutide 10
and 20 mg) between 2nd and 4th weeks were chosen as metrics
to build the empirical relationships between exposure and
responses in MBMA. At the same time, the maximum reduc-
tion responses of FPG in the drug group were used as metrics
to perform HbA1c data modeling. MBMA has demonstrated
that this approach with empirical metrics adequately described
248 H.Q. Li et al.the proﬁles of FPG and HbA1c over time, as seen in Figs. 1
and 2.
Despite MBMA approach being utilized to compare efﬁ-
cacy results of different medications with different durations
and dosing regimens, it has been extended to delineate net efﬁ-
cacy results of taspoglutide from placebo effects in large clini-
cal trials. The Emax model acted as linkage to integrate
placebo and taspoglutide information from different durations
with different concomitant medications during therapeutic
process and treatment backgrounds before starting clinical tri-
als. In quantitative analysis process, the drug or placebo
directly regulated the changes of FPG and reduced the levels
of FPG in type 2 diabetic patients; subsequently the changes
of FPG derived from inﬂuence of taspoglutide directly inﬂu-
enced the levels of HbA1c. The information on average HbA1c
change is available to further evaluate the patient status with
type 2 diabetes, as an increase of 0.2% HbA1c per year has
reﬂected the rate of disease progression of patients (de
Winter et al., 2006). Therefore through quantitative models,
the net effects of drug treatment (Shang et al., 2009) delineated
from placebo responses can be conveniently assessed, and
more information about glycemic control for patients with
type 2 diabetes can be obtained.
Taspoglutide produced clinically meaningful improvements
in glycemic control in patients treated with 10 and 20 mg dos-
ing regimens. The reduction in FPG for taspoglutide 20 mg
was 2.1 ± 0.2 mmol/l (Pratley et al., 2013) after 24 weeks
while the model population predicted value in FPG reduction
for drug was 2.39 mmol/l, which indicated that taspoglutide
20 mg already produced the maximum glycemic control in clin-
ical trials. An Emax model for the change in FPG showed that
80% of maximal reduction in FPG adjusted from placebo
response was achieved at drug plasma concentration of
101.2 pmol/l (IC80_F), which was already reached and generally
maintained above when taspoglutide 20 mg once weekly was
given to type 2 diabetes patients (Ratner et al., 2010). Thus
it can be seen that taspoglutide 20 mg seems to be an optimal
dose for type 2 diabetes patients in clinical trials. However,
treatment of taspoglutide 20 mg led to high subsequent rates
of discontinuation due to substantial rates of gastrointestinal
intolerability and allergic reactions (Rosenstock et al., 2013),
therefore the dosage adjustment of taspoglutide should be rec-
ommended for type 2 diabetes patients by considering the
adverse events in clinical trials.
Likewise, a HbA1c reduction of 1.74% in the drug group
compared with 0.253% of the placebo group was estimated
in quantitative model and was almost consistent with the pub-
lished data in clinical trial (Henry et al., 2012), where glycemic
control improved to a greater extent in taspoglutide treated
patients with robust reduction in HbA1c up to 1.89% from
baseline of 8.14% (6.6–10.4%). The ﬁrst-order rate constant
(kdrug_Hb), which described the effect of taspoglutide, sug-
gested that steady state would be achieved after 3.5 months.
MBMA also demonstrated that the level of FPG could be
much more quickly controlled than that of HbA1c when
taspoglutide was subcutaneously administrated to type 2 dia-
betes patients through multiple dosing regimens in clinical tri-
als. The steady state of FPG could be achieved after 1.7 weeks
while that of HbA1c could be achieved 3.5 months, and
the time delay between FPG and HbA1c was signiﬁcantly
obvious in controlling type 2 diabetes disease progressions
by using taspoglutide. Therefore, the therapeutic duration oftaspoglutide could be optimized in clinical treatment of type
2 diabetes disease through half-lives of FPG and HbA1c.
MBMA has several limitations as the same as the tradi-
tional meta-analysis. This approach adopts available informa-
tion from public reports or literatures and may be subject to
publication bias. The metrics for characterizing the relation-
ship between exposure and efﬁcacy empirically rely on the
average concentrations of 10 and 20 mg doses of taspoglutide
and may decrease the prediction ability of quantitative models.
In addition, differences in FPG and HbA1c assay applied dur-
ing the clinical development should be noted concerning the
different labs, operators and analytical instruments. Despite
these existing differences in the measurement of PD data, a
similar relationship to outcome was observed across different
clinical trials. Furthermore, covariates were not included in
ﬁnal models and might have impacts on model parameters.
However, a major advantage of this MBMA is a ﬂexible appli-
cation of mathematical equations for leveraging prior clinical
information without consideration of time delay effects
between PK and PD. This MBMA approach will continue to
be used to delineate similar drug efﬁcacy from the placebo
response in clinical trials, such as liraglutide and exenatide
extended release.
5. Conclusions
In summary, two quantitative models were developed to delin-
eate the net efﬁcacy of taspoglutide from the response of pla-
cebo in large clinical trials. The metrics of taspoglutide
appear to be useful parameters related to FPG and HbA1c
data modeling. Exposure to FPG and FPG to HbA1c relation-
ships informed by MBMA can be leveraged to support study
designs including optimization of dose and duration of
therapy.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jsps.2014.
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